How have RDHL shares performed in 2024?

RedHill Biopharma's stock was trading at $1.46 at the beginning of 2024. Since then, RDHL shares have decreased by 69.0% and is now trading at $0.4520. View the best growth stocks for 2024 here .

When is RedHill Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, June 10th 2024. View our RDHL earnings forecast .

How were RedHill Biopharma's earnings last quarter?

RedHill Biopharma Ltd. (NASDAQ:RDHL) posted its quarterly earnings data on Tuesday, November, 30th. The biotechnology company reported ($20.00) earnings per share for the quarter, missing analysts' consensus estimates of ($19.20) by $0.80. The biotechnology company had revenue of $21.61 million for the quarter, compared to analysts' expectations of $23.41 million. During the same quarter in the prior year, the business earned ($20.00) EPS.

When did RedHill Biopharma's stock split?

RedHill Biopharma shares reverse split on Thursday, March 23rd 2023. The 1-40 reverse split was announced on Thursday, March 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of RedHill Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RedHill Biopharma investors own include Agenus (AGEN) , Sorrento Therapeutics (SRNE) , Sangamo Therapeutics (SGMO) , Verastem (VSTM) , Amarin (AMRN) , Aralez Pharmaceuticals (ARLZ) , Inovio Pharmaceuticals (INO) , Tesla (TSLA) , Gilead Sciences (GILD) and NVIDIA (NVDA) .

How do I buy shares of RedHill Biopharma?

Shares of RDHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:RDHL

RedHill Biopharma (RDHL) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free RDHL Stock Alerts

$0.45

+0.03 (+7.41%)

(As of 05:37 PM ET)

Compare

Today's Range: $0.40
▼
$0.46
50-Day Range: $0.38
▼
$0.62
52-Week Range: $0.26
▼
$3.28

Volume: 330,218 shs
Average Volume: 1.14 million shs
Market Capitalization: $13.43 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get RedHill Biopharma alerts:

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About RedHill Biopharma Stock (NASDAQ:RDHL)

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

RDHL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RDHL Stock News Headlines

April 18, 2024 | americanbankingnews.com

RedHill Biopharma (NASDAQ:RDHL) Now Covered by StockNews.com

April 10, 2024 | finance.yahoo.com

RedHill Biopharma Full Year 2023 Earnings: EPS: US$4.00 (vs US$46.29 loss in FY 2022)

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 9, 2024 | bizjournals.com

Raleigh pharma weighs divesting commercial operations

April 8, 2024 | finanznachrichten.de

RedHill Biopharma Ltd.: RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights

April 8, 2024 | finance.yahoo.com

RedHill Biopharma Ltd. (2RH0.F)

April 8, 2024 | prnewswire.com

RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights

April 2, 2024 | finance.yahoo.com

RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 11, 2024 | markets.businessinsider.com

RedHill Biopharma Receives New Patent For H. Pylori Treatment Talicia

March 11, 2024 | finance.yahoo.com

RedHill Announces New USPTO Patent Covering Talicia® Through 2034

March 5, 2024 | finance.yahoo.com

RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs

February 20, 2024 | finance.yahoo.com

RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication

February 20, 2024 | prnewswire.com

RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication

February 16, 2024 | barrons.com

RedHill Biopharma Ltd. ADR

January 26, 2024 | finance.yahoo.com

RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering

January 25, 2024 | msn.com

RedHill gains after new patent grant for Talicia for H. pylori treatment through 2042

January 25, 2024 | finance.yahoo.com

RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042

January 25, 2024 | finance.yahoo.com

RedHill Biopharma Announces $8 Million Registered Direct Offering

January 24, 2024 | benzinga.com

Why Redhill Biopharma Stock Is Moving Higher

December 20, 2023 | msn.com

RedHill's Investigational COVID-19 Drugs Combined With Gilead's Show Effect Against Ebola

December 20, 2023 | markets.businessinsider.com

RedHill Announces Results Of A New U.S. Army-funded In Vivo Ebola Virus Study

December 20, 2023 | msn.com

RedHill shares rally 20% on positive data for two antiviral drugs

December 20, 2023 | finance.yahoo.com

RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola

December 12, 2023 | msn.com

RedHill Biopharma regains compliance with Nasdaq listing rule

December 4, 2023 | finance.yahoo.com

RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study

November 30, 2023 | benzinga.com

Redhill Biopharma Stock (NASDAQ:RDHL), Short Interest Report

See More Headlines

Receive RDHL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RedHill Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/30/2021
Today: 4/19/2024
Next Earnings (Estimated): 6/10/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:RDHL
CUSIP: N/A
CIK: 1553846
Web: www.redhillbio.com
Phone: 972-3541-3131
Fax: 972-3541-3144
Employees: 113
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.84
Quick Ratio: 0.61

Sales & Book Value

Annual Sales: $6.53 million
Price / Sales: 1.94
Cash Flow: $1.47 per share
Price / Cash Flow: 0.29
Book Value: $0.11 per share
Price / Book: 3.88

Miscellaneous

Outstanding Shares: 29,700,000
Free Float: 27,680,000
Market Cap: $12.68 million
Optionable: No Data
Beta: 3.45

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Mr. Dror Ben-Asher (Age 58)
Co-Founder, Chairman & CEO
Comp: $594.61k
Mr. Razi Ingber (Age 40)
Chief Financial Officer
Comp: $339.82k
Mr. Gilead Raday MPhil (Age 49)
MSc, Chief Operating Officer
Comp: $365.56k
Mr. Adi Frish (Age 54)
Chief Corporate & Business Development Officer
Comp: $339.3k
Mr. Rick D. Scruggs (Age 64)
Chief Commercial Officer, President of RedHill Biopharma Inc. & Director
Comp: $469.8k
Ms. Alexandra Okmian
Senior Business Development & Investor Relations Manager
Dr. Reza Fathi Ph.D. (Age 69)
Senior Vice President of Research & Development
Comp: $299.29k
Mr. Guy Goldberg J.D. (Age 48)
Chief Business Officer
Comp: $338.13k
Dr. June S. Almenoff FACP (Age 67)
M.D., Ph.D., Chief Medical Officer
Ms. Patricia Anderson B.Sc. RAC
Senior Vice President of Regulatory Affairs

Key Competitors

View All Competitors

RDHL Stock Analysis - Frequently Asked Questions

How have RDHL shares performed in 2024?: RedHill Biopharma's stock was trading at $1.46 at the beginning of 2024. Since then, RDHL shares have decreased by 69.0% and is now trading at $0.4520.
View the best growth stocks for 2024 here.
When is RedHill Biopharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, June 10th 2024.
View our RDHL earnings forecast.
How were RedHill Biopharma's earnings last quarter?: RedHill Biopharma Ltd. (NASDAQ:RDHL) posted its quarterly earnings data on Tuesday, November, 30th. The biotechnology company reported ($20.00) earnings per share for the quarter, missing analysts' consensus estimates of ($19.20) by $0.80. The biotechnology company had revenue of $21.61 million for the quarter, compared to analysts' expectations of $23.41 million. During the same quarter in the prior year, the business earned ($20.00) EPS.
When did RedHill Biopharma's stock split?: RedHill Biopharma shares reverse split on Thursday, March 23rd 2023. The 1-40 reverse split was announced on Thursday, March 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of RedHill Biopharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other RedHill Biopharma investors own include Agenus (AGEN), Sorrento Therapeutics (SRNE), Sangamo Therapeutics (SGMO), Verastem (VSTM), Amarin (AMRN), Aralez Pharmaceuticals (ARLZ), Inovio Pharmaceuticals (INO), Tesla (TSLA), Gilead Sciences (GILD) and NVIDIA (NVDA).
How do I buy shares of RedHill Biopharma?: Shares of RDHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RDHL) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial